Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1649JXM

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1	Feb 2	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	Expanded CAplus Coverage of US, Japanese, WIPO, EPO, and German patents
NEWS	3	Feb 1	Addition of Machine-Translated Abstracts to CAplus
NEWS	4	Feb 28	Patent Information Now Searchable in CAOLD
NEWS	5	Mar 20	INPADOC: PRODUCER WARNING ABOUT DATA DELAYS
NEWS	6	Mar 22	NEW FEATURES IN INPADOC - RANGE SEARCHING AND NEW SDI/UPDATE SEARCH FIELD
NEWS	7	May 1	Beilstein Abstracts on STN - FILE BABS
NEWS	8	May 1	RN CROSSOVER AND ANSWER SIZE LIMITS INCREASED
NEWS	9	May 1	AIDSLINE has been reloaded
NEWS	10	May 1	Searching Y2-K compliant Patent Numbers
NEWS	11	May 9	Sequence Similarity Batch Search in DGENE
NEWS	12	May 19	Weekly Statistics for New Entries now available in INPADOC
NEWS	13	May 22	CITED REFERENCES NOW AVAILABLE IN CAPLUS AND CA FILE
NEWS	14	May 22	POSTPROCESSING OF SEARCH RESULTS MAY BE AFFECTED BY ADDITION OF CITED REFERENCES TO CAPLUS, CA, REGISTRY, CASREACT, MARPAT, and MARPATPREV
NEWS	15	Jun 2	KOREAN PATENTS NOW IN CAS DATABASES
NEWS	16	Jun 20	WIPO/PCT Patents Fulltext Database now on STN

NEWS EXPRESS	FREE UPGRADE 5.0C NOW AVAILABLE
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:28:51 ON 22 JUN 2000

=> file medline biosis embase caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION

FULL ESTIMATED COST 0.42 0.42

FILE 'MEDLINE' ENTERED AT 15:29:52 ON 22 JUN 2000

FILE 'BIOSIS' ENTERED AT 15:29:52 ON 22 JUN 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 15:29:52 ON 22 JUN 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:29:52 ON 22 JUN 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s trre (s) polypeptide

L1 0 TRRE (S) POLYPEPTIDE

=> s trre (s) protein

L2 0 TRRE (S) PROTEIN

=> s trre

L3 9 TRRE

=> dup rem l3

PROCESSING COMPLETED FOR L3
L4 6 DUP REM L3 (3 DUPLICATES REMOVED)

=> d l4 ibib kwic

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:736749 CAPLUS
DOCUMENT NUMBER: 132:2794
TITLE: Modulators affecting tumor necrosis factor receptor-releasing enzyme activity
INVENTOR(S): Gatanaga, Tetsuya; Granger, Gale A.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958559	A2	19991118	WO 1999-US10793	19990514
WO 9958559	A3	20000120		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1998-81385 19980514
AB The biol. effects of the cytokine tumor necrosis factor (TNF) are mediated by binding to receptors on the surface of cells. Nine new proteins and polynucleotides are provided that promote enzymic cleavage and release of TNF receptors. The isolated polynucleotides have the following properties: (a) the sequence is expressed at the mRNA level in Jurkat T cells; (b) when COS-1 cells expressing TNF-receptor are genetically transformed to express the sequence, the cells have increased enzymic activity for cleaving and releasing the receptor. Also provided are screening methods for identifying addnl. compds. that influence TNF receptor shedding. **TRRE** activity alleviates septic shock and decreases tumor necrotizing activity, and the modulator expression products are effective in treating septic shock. As the active ingredient in a pharmaceutical compn., the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathol. of disease.

=> file medline biosis embase caplus uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.87	12.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.56	-0.56

FILE 'MEDLINE' ENTERED AT 15:32:44 ON 22 JUN 2000

FILE 'BIOSIS' ENTERED AT 15:32:44 ON 22 JUN 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 15:32:44 ON 22 JUN 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:32:44 ON 22 JUN 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:32:44 ON 22 JUN 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s trre

L5 11 TRRE

=> dup rem l5

PROCESSING COMPLETED FOR L5
L6 8 DUP REM L5 (3 DUPLICATES REMOVED)

=> d l6 ibib kwic total

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:736749 CAPLUS

DOCUMENT NUMBER: 132:2794
TITLE: Modulators affecting tumor necrosis factor receptor-releasing enzyme activity
INVENTOR(S): Gatanaga, Tetsuya; Granger, Gale A.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958559	A2	19991118	WO 1999-US10793	19990514
WO 9958559	A3	20000120		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-81385 19980514

AB The biol. effects of the cytokine tumor necrosis factor (TNF) are mediated by binding to receptors on the surface of cells. Nine new proteins and polynucleotides are provided that promote enzymic cleavage and release of TNF receptors. The isolated polynucleotides have the following properties: (a) the sequence is expressed at the mRNA level in Jurkat T cells; (b) when COS-1 cells expressing TNF-receptor are genetically transformed to express the sequence, the cells have increased enzymic activity for cleaving and releasing the receptor. Also provided are screening methods for identifying addnl. compds. that influence TNF receptor shedding. **TRRE** activity alleviates septic shock and decreases tumor necrotizing activity, and the modulator expression products are effective in treating septic shock. As the active ingredient in a pharmaceutical compn., the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathol. of disease.

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1998:324897 CAPLUS
DOCUMENT NUMBER: 129:13976
TITLE: Isolated tumor necrosis factor receptor releasing enzyme and pharmaceutical compositions comprising the enzyme
INVENTOR(S): Granger, Gale A.; Gatanaga, Tetsuya
PATENT ASSIGNEE(S): Regents of the University of California, USA; Granger, Gale A.; Gatanaga, Tetsuya
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9820140	A1	19980514	WO 1997-US19930	19971105
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9851621	A1	19980529	AU 1998-51621	19971105
EP 938548	A1	19990901	EP 1997-946457	19971105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NO 9902187	A	19990701	NO 1999-2187	19990505
PRIORITY APPLN. INFO.:			US 1996-30761	19961106
			WO 1997-US19930	19971105

AB A human tumor necrosis factor receptor releasing enzyme (**TRRE**) is prepd. from a cultured human cell line THP-1 (human monocytic leukemia) stimulated with PMA and characterized. The native form of **TRRE** exhibits a mol. wt. of 120 kDa on SDS-PAGE. Its enzyme activity is sensitive to metalloprotease inhibitor, but not to serine or cysteine protease inhibitor. A compn. contg. **TRRE** for treating a disease assocd. with altered levels of tumor necrosis factor is also described. Also claimed are methods of (1) diagnosing and treating cancer or inflammation assocd. with TREE and (2) administration of pharmaceutical compns. contg. TREE. Preferably, the **TRRE** activity is regulated local to the site of the condition to be treated. In the case of diseases assocd. with elevated levels of TNF, such as rheumatoid arthritis, **TRRE** is administered to the site of inflammation in an amt. sufficient to decrease the local levels of TNF. In the case of diseases, such as cancer, that benefit from increased levels of TNF, the level of **TRRE** is decreased at the disease site.

L6 ANSWER 3 OF 8 BIOSIS COPYRIGHT 2000 BIOSIS
ACCESSION NUMBER: 1996:257458 BIOSIS
DOCUMENT NUMBER: PREV199698813587
TITLE: Identification and characterization of soluble TNF receptor releasing enzyme (**TRRE**) from PMA-stimulated human monocytic THP-1 cells.
AUTHOR(S): Katsura, K. (1); Park, M. (1); Gatanaga, M. (1); Takishima, K.; Granger, G. A. (1); Gatanaga, T. (1)
CORPORATE SOURCE: (1) Univ. Calif., Irvine, CA USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (1996) Vol. 37, No. 0, pp. 492. Meeting Info.: 87th Annual Meeting of the American Association for Cancer Research Washington, D.C., USA April 20-24, 1996
ISSN: 0197-016X.
DOCUMENT TYPE: Conference
LANGUAGE: English

TI Identification and characterization of soluble TNF receptor releasing enzyme (**TRRE**) from PMA-stimulated human monocytic THP-1 cells.

L6 ANSWER 4 OF 8 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 96222497 MEDLINE
DOCUMENT NUMBER: 96222497
TITLE: Identification of the proteolytic enzyme which cleaves human p75 TNF receptor in vitro.
AUTHOR: Katsura K; Park M; Gatanaga M; Yu E C; Takishima K; Granger G A; Gatanaga T
CORPORATE SOURCE: Department of Molecular Biology and Biochemistry, University of California, Irvine 92717-3900, USA.
SOURCE: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996 May 15) 222 (2) 298-302.
Journal code: 9Y8. ISSN: 0006-291X.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Cancer Journals
ENTRY MONTH: 199610
AB . . . fragments, respectively. In this study, the enzymatic activity involved in the cleavage of human p75 TNF-R, named TNF-R releasing enzyme (**TRRE**), was identified in the culture supernatant of PMA-stimulated THP-1 cells using an activity assay system established by our group. When THP-1 cells were stimulated with PMA, **TRRE** was released rapidly into the supernatant, reaching maximal activity within 3 hours. The release of **TRRE** into the culture supernatant depended on the concentration of PMA and FCS. **TRRE** activity was partially inhibited by chelating agents, suggesting that **TRRE** may be a metallo-protease-like enzyme. This is the first successful attempt to establish a stable **TRRE** source with a reliable assay system.

L6 ANSWER 5 OF 8 USPATFULL
ACCESSION NUMBER: 93:83356 USPATFULL
TITLE: Facsimile apparatus comprising means for continuously transmitting plural groups of image data to the same receiver party
INVENTOR(S): Hamano, Hiroaki, Osaka, Japan
Nakajima, Akio, Toyokawa, Japan
PATENT ASSIGNEE(S): Minolta Camera Kabushiki Kaisha, Osaka, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5251043	19931005
APPLICATION INFO.:	US 1991-776636	19911015 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-277402	19901015
	JP 1990-277403	19901015
	JP 1990-277404	19901015

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Coles, Sr., Edward L.
ASSISTANT EXAMINER: Rogers, Scott A.
LEGAL REPRESENTATIVE: Willian Brinks Olds Hofer Gilson & Lione
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 31 Drawing Page(s)
LINE COUNT: 1632
DETD . . . key 52 is referred to as a TR key, and the transmission reservation key 57 is referred to as a **TRRE** key.

L6 ANSWER 6 OF 8 BIOSIS COPYRIGHT 2000 BIOSIS
ACCESSION NUMBER: 1993:227104 BIOSIS
DOCUMENT NUMBER: PREV199395118279
TITLE: Do birch trees (Betula pendula) grow better if foraged by wood ants.
AUTHOR(S): Mahdi, T.; Whittaker, J. B.
CORPORATE SOURCE: Biological Sci. Div., Inst. Environmental and Biological Sci., Univ. Lancaster, Lancaster LA1 4YQ UK
SOURCE: Journal of Animal Ecology, (1993) Vol. 62, No. 1, pp. 101-116.
ISSN: 0021-8790.
DOCUMENT TYPE: Article
LANGUAGE: English
AB. . . . of the insect herbivore community on Betula pendula is markedly changed by F. rufa predation, the effect of this on **trre** growth is slight.

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1985:1908 CAPLUS
DOCUMENT NUMBER: 102:1908
TITLE: The tolerance of tree lucerne to some soil-applied herbicide
AUTHOR(S): Hurrell, G. A.; Bourdot, G. W.
CORPORATE SOURCE: Agric. Res. Div., MAF, Lincoln, N. Z.
SOURCE: Proc. N. Z. Weed Pest Control Conf. (1984), 37th, 210-12
CODEN: PZWPAL; ISSN: 0370-2804
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Plant growth and development
(by **trre** lucerne, soil-applied herbicides effect on)

L6 ANSWER 8 OF 8 USPATFULL
ACCESSION NUMBER: 78:39684 USPATFULL
TITLE: Method for data transmission and a system for carrying out the method
INVENTOR(S): Westman, Kjell Harry, Vallingby, Sweden
PATENT ASSIGNEE(S): U.S. Philips Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4103288	19780725
APPLICATION INFO.:	US 1976-723155	19760914 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1975-10432	19750918

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Pitts, Harold I.
LEGAL REPRESENTATIVE: Trifari, Frank R.; Biren, Steven R.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1087
DETD . . . and input of which are connected to a central station 1 via a belonging modem M1 and a transmission/reception circuit **TRRE**, respectively. To the loop are connected four terminal stations 2, 3, 4, 5 via the belonging modems M2, M3, M4. . .
DETD In FIG. 5 is disclosed an embodiment of the transmission/reception

circuit **TRRE**, through which the central station 1 (TC) (FIG. 1) is connected to the series transmission loop. The horizontal line at.

. . figure represents the border line with respect to the central station 1 with the signals shown which are interchanged between **TRRE** and TC. The horizontal line at the bottom of the figure represents the border line with respect to the transmission. . .

DETD **TRRE** is composed of a central control unit CO, in which is comprised control circuits of a type well known by. . .

DETD On the input side **TRRE** comprises a central control unit CO to be described in more detail with reference to FIG. 7 and is furthermore.

. .

DETD . . . diagram of the DT, DTI respectively, circuit comprised in the connection circuit (FIG. 4) of each terminal and in the **TRRE** circuit of the central station (FIG. 5).

DETD The central control unit CO (FIG. 5) of **TRRE** is disclosed in FIG. 7. CO is composed of a 4 bit counter COUNT4 which may be controlled so as. . .

DETD . . . and DT in all terminal stations, which are thereby brought into synchronism. The SYN characters are received in IDBR of **TRRE** after having circulated the loop and are decoded in DTI, which will then activate its SYN output, which will in. . .

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.99	27.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.11	-1.67

STN INTERNATIONAL LOGOFF AT 15:33:26 ON 22 JUN 2000

09700354 Results

SEQ ID NO: 9

```
RESULT  10
G22793/c
LOCUS       G22793        405 bp    DNA             STS       31-MAY-1996
DEFINITION  human STS WI-11758, sequence tagged site.
ACCESSION   G22793
VERSION     G22793.1  GI:1343119
KEYWORDS    STS; STS sequence; primer; sequence tagged site.
SOURCE      human STSs derived from sequences in dbEST and the Unigene
            collection.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 405)
  AUTHORS   Hudson,T.
  TITLE     Whitehead Institute/MIT Center for Genome Research; Physically
            Mapped STSs
  JOURNAL   Unpublished (1995)
COMMENT
            Contact: Thomas Hudson
            Whitehead Institute/MIT Center for Genome Research
            Whitehead Institute for Biomedical Research
            9 Cambridge Center, Cambridge MA 02142 USA
            Tel: 617 252 1900
            Fax: 617 252 1902
            Email: thudson@genome.wi.mit.edu

            Primer A: TTTTTCCTCTTTTATTAAGTCCGC
            Primer B: TGATGGTGATCTTGGCACTC
            STS size: 127
            PCR Profile:
                  Presoak:
                  Denaturation:
                  Annealing: 56 degrees C
                  Polymerization:
                  PCR Cycles: 35
                  Thermal Cycler:
            Protocol:
                Template: 10 ng
                Primer: each 5 pM
                dNTPs: each 4 nM
                Taq Polymerase: 0.025 units/ul
                Total Vol: 20 ul

            Buffer:
                MgCl2: 1.5 mM
                KCl: 50 mM
                Tris-HCL: 10 mM
                pH: 9.3

            Derived from dbEST (genbank accession R12670).
FEATURES             Location/Qualifiers
     source          1. .405
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /map="355.3 cR from top of Chr17 linkage group"
     STS             14. .140
     primer_bind     14. .37
     primer_bind     complement(121. .140)
BASE COUNT       92 a    107 c    100 g    100 t      6 others
ORIGIN
```

```
  Query Match             27.9%;  Score 330.6;  DB 54;  Length 405;
  Best Local Similarity   96.7%;  Pred. No. 1.8e-69;
  Matches  356;  Conservative    0;  Mismatches    9;  Indels    3;  Gaps    2;
```

```
Qy    756 CTGGAGCCTAAGCTGGACC--TGCTACTGGAGAAGACCAAGGAGCTGCAGAAGCTGATTG 813
          ||||||||||||||||||    |||||||| ||| ||||||||||||||||||||| ||
Db    400 CTGGAGCCTAAGCTGGACCCTGCCTACTGGANAAGCCCAAGGAGCTGCAGAAGCTGANTG 341

Qy    814 AAGCTGA-CATCTCCAAGAGGTACAGCGGGCGCCCTGTGAACCTGATGGGAACCTCTCTG 872
          ||||||| ||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db    340 AAGCTGACCATCTCCAANAGGTACAGCGGGCGCCCTGTGAACCTGATGGGAACCTCTCTG 281

Qy    873 TGACACCCTCCGTGTTCTTGCCTGCCCATCTTCTCCGCTTTTGGGATGAAGATGATAGCC 932
          ||| |||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db    280 TGANACCCTCCGTGNTCTTGCCTGCCCATCTTCTCCGCTTTTGGGATGAAGATGATAGCC 221

Qy    933 AGGGCTGTTGTTTTGGGGCCCTTCAAGGCAAAAGACCAGGCTGACTGGAAGATGGAAAGC 992
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    220 AGGGCTGTTGTTTTGGGGCCCTTCAAGGCAAAAGACCAGGCTGACTGGAAGATGGAAAGC 161

Qy    993 CACAGGAAGGAAGCGGCACCTGATGGTGATCTTGGCACTCTCCATGTTCTCTACAAGAAG 1052
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    160 CACAGGAAGGAAGCGGCACCTGATGGTGATCTTGGCACTCTCCATGTTCTCTACAAGAAG 101

Qy   1053 CTGTGGTGATTGGCCCTGTGGTCTATCAGGCGAAAACCACAGATTCTCCTTCTAGTTAGT 1112
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    100 CTGTGGTGATTGGCCCTGTGGTCTATCAGGCGAAAACCACAGATTCTCCTTCTAGTTAGT 41

Qy   1113 ATAGCGCA 1120
          |||||| |
Db     40 ATAGCGGA 33
```

```
RESULT   1
AAZ38861
ID   AAZ38861 standard; DNA; 1187 BP.
XX
AC   AAZ38861;
XX
DT   17-FEB-2000  (first entry)
XX
DE   Human Jurkat cell clone P2-14 AIM9 which affects TRRE activity.
XX
KW   Human; Jurkat cell; tumour necrosis factor receptor releasing enzyme;
KW   TRRE; cytokine; TNF; identification; cytostatic; anti-inflammatory;
KW   cardiant; immunomodulator; antiarthritic; antibacterial; cancer;
KW   heart failure; cachexia; inflammation; endotoxic shock; arthritis;
KW   multiple sclerosis; sepsis; ds.
XX
OS   Homo sapiens.
XX
PN   WO9958559-A2.
XX
PD   18-NOV-1999.
XX
PF   14-MAY-1999;   99WO-US10793.
XX
PR   14-MAY-1998;   98US-0081385.
XX
PA   (REGC ) UNIV CALIFORNIA.
XX
PI   Gatanaga T,  Granger GA;
XX
DR   WPI; 2000-039067/03.
XX
PT   Tumor necrosis factor receptor releasing enzyme modulators and
PT   polynucleotides  -
XX
PS   Claim 2; Page 68; 106pp; English.
XX
CC   The present invention describes isolated polynucleotides (A) comprising a
CC   sequence expressed at the mRNA level in Jurkat T cells and showing
CC   increased enzymatic activity for cleaving and releasing the tumour
CC   necrosis factor (TNF) receptor in genetically modified COS-1 cells
```

CC expressing the receptor. The present sequence represents a specifically
CC claimed clone which affects tumour necrosis factor receptor releasing
CC enzyme (TRRE) activity. Methods from the present invention can be used to
CC assess a disease condition associated with altered TRRE activity. The
CC polypeptides, polynucleotides and antibodies can be used to decrease or
CC increase signal transduction from a cytokine in a cell. The polypeptides,
CC polynucleotides and antibodies may be used to treat heart failure,
CC cachexia, inflammation, endotoxic shock, arthritis, multiple sclerosis
CC and sepsis, and cancer.
XX
SQ Sequence 1187 BP; 278 A; 288 C; 369 G; 252 T; 0 other;

Query Match 100.0%; Score 1187; DB 21; Length 1187;
Best Local Similarity 100.0%; Pred. No. 5.4e-281;
Matches 1187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 GAGCTCGCGCGCCTGCAGGTCGACACTAGTGGATCCAAAGAATTCGGCACGAGGGAAACT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 gagctcgcgcgcctgcaggtcgacactagtggatccaaagaattcggcacgagggaaact 60

Qy      61 CAACGGTGTACGAGTGGAGGACAGGGACAGAGCCCTCTGTGGTGGAACGACCCCACCTCG 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 caacggtgtacgagtggaggacagggacagagccctctgtggtggaacgaccccacctcg 120

Qy     121 AGGAGCTTCCTGAGCAGGTGGCAGAAGATGCGATTGACTGGGGCGACTTTGGGGTAGAGG 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 aggagcttcctgagcaggtggcagaagatgcgattgactggggcgactttggggtagagg 180

Qy     181 CAGTGTCTGAGGGGACTGACTCTGGCATCTCTGCCGAGGCTGCTGGAATCGACTGGGGCA 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 cagtgtctgaggggactgactctggcatctctgccgaggctgctggaatcgactggggca 240

Qy     241 TCTTCCCGGAATCAGATTCAAAGGATCCTGGAGGTGATGGGATAGACTGGGGAGACGATG 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 tcttcccggaatcagattcaaaggatcctggaggtgatgggatagactggggagacgatg 300

Qy     301 CTGTTGCTTTGCAGATCACAGTGCTGGAAGCAGGAACCCAGGCTCCAGAAGGTGTTGCCA 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 ctgttgctttgcagatcacagtgctggaagcaggaacccaggctccagaaggtgttgcca 360

Qy     361 GGGGCCCAGATGCCCTGACACTGCTTGAATACACTGAGACCCGGAATCAGTTCCTTGATG 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 ggggcccagatgccctgacactgcttgaatacactgagacccggaatcagttccttgatg 420

Qy     421 AGCTCATGGAGCTTGAGATCTTCTTAGCCCAGAGAGCAGTGGAGTTGAGTGAGGAGGCAG 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 agctcatggagcttgagatcttcttagcccagagagcagtggagttgagtgaggaggcag 480

Qy     481 ATGTCCTGTCTGTGAGCCAGTTCCAGCTGGCTCCAGCCATCCTGCAGGGCCAGACCAAAG 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 atgtcctgtctgtgagccagttccagctggctccagccatcctgcagggccagaccaaag 540

Qy     541 AGAAGATGGTTACCATGGTGTCAGTGCTGGAGGATCTGATTGGCAAGCTTACCAGTCTTC 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 agaagatggttaccatggtgtcagtgctggaggatctgattggcaagcttaccagtcttc 600

Qy     601 AGCTGCAACACCTGTTTATGATCCTGGCCTCACCAAGGTATGTGGACCGAGTGACTGAAT 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 agctgcaacacctgtttatgatcctggcctcaccaaggtatgtggaccgagtgactgaat 660

Qy     661 TCCTCCAGCAAAAGCTGAAGCAGTCCCAGCTGCTGGCTTTGAAGAAAGAGCTGATGGTGC 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 tcctccagcaaaagctgaagcagtcccagctgctggctttgaagaaagagctgatggtgc 720

Qy     721 AGAAGCAGCAGGAGGCACTTGAGGAGCAGGCGGCTCTGGAGCCTAAGCTGGACCTGCTAC 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 agaagcagcaggaggcacttgaggagcaggcggctctggagcctaagctggacctgctac 780

Qy     781 TGGAGAAGACCAAGGAGCTGCAGAAGCTGATTGAAGCTGACATCTCCAAGAGGTACAGCG 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db    781 tggagaagaccaaggagctgcagaagctgattgaagctgacatctccaagaggtacagcg 840

Qy    841 GGCGCCCTGTGAACCTGATGGGAACCTCTCTGTGACACCCTCCGTGTTCTTGCCTGCCCA 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    841 ggcgccctgtgaacctgatgggaacctctctgtgacaccctccgtgttcttgcctgccca 900

Qy    901 TCTTCTCCGCTTTTGGGATGAAGATGATAGCCAGGGCTGTTGTTTTGGGGCCCTTCAAGG 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    901 tcttctccgcttttgggatgaagatgatagccagggctgttgttttggggcccttcaagg 960

Qy    961 CAAAAGACCAGGCTGACTGGAAGATGGAAAGCCACAGGAAGGAAGCGGCACCTGATGGTG 1020
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    961 caaaagaccaggctgactggaagatggaaagccacaggaaggaagcggcacctgatggtg 1020

Qy   1021 ATCTTGGCACTCTCCATGTTCTCTACAAGAAGCTGTGGTGATTGGCCCTGTGGTCTATCA 1080
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1021 atcttggcactctccatgttctctacaagaagctgtggtgattggccctgtggtctatca 1080

Qy   1081 GGCGAAAACCACAGATTCTCCTTCTAGTTAGTATAGCGCAAAAAGCTTCTCGAGAGTACT 1140
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1081 ggcgaaaaccacagattctccttctagttagtatagcgcaaaaagcttctcgagagtact 1140

Qy   1141 TCTAGAGCGGCCGCGGGCCCATCGATTTTCCACCCGGGTGGGGTACC 1187
          ||||||||||||||||||||||||||||||||||||||||||||||
Db   1141 tctagagcggccgcgggcccatcgattttccacccgggtggggtacc 1187
```

```
RESULT   4
AAX10455/c
ID   AAX10455 standard; DNA; 127 BP.
XX
AC   AAX10455;
XX
DT   30-MAR-1999  (first entry)
XX
DE   Human biallelic polymorphic DNA fragment WI-11758.
XX
KW   Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW   detection; phenotypic typing; characteristic; infection; hereditary;
KW   autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW   treatment; marker; ss.
XX
OS   Homo sapiens.
XX
PN   WO9820165-A2.
XX
PD   14-MAY-1998.
XX
PF   05-NOV-1997;   97WO-US20313.
XX
PR   06-NOV-1996;   96US-0030455.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
PI   Hudson T,  Lander ES,  Wang D;
XX
DR   WPI; 1998-286974/25.
XX
PT   New isolated nucleic acid segments from the human genome - used for
PT   determining polymorphic forms for use in e.g. forensics, paternity
PT   testing or phenotypic typing for disease
XX
PS   Claim 1; Page 52; 310pp; English.
XX
CC   AAX10269-X12937 are human DNA fragments which contain biallelic
CC   polymorphic markers which have been isolated using the primers
CC   represented in AAX09121-X10268. The base occupying the polymorphic site
CC   is indicated by the appropriate IUPAC-IUB ambiguity code. These fragments
CC   can be used in methods for determining polymorphic forms in an individual
CC   for use in e.g. forensics, paternity testing or for phenotypic typing for
CC   diseases such as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan
```

CC syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease,
CC familial hypercholesterolemia, polycystic kidney disease, hereditary
CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC autoimmune diseases, inflammation, cancer, diseases of the nervous
CC system, infection by pathogenic microorganisms, and characteristics such
CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC endurance, fertility, and susceptibility or receptivity to particular
CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC segments can also be used to produce medicaments for the treatment or
CC prophylaxis of such diseases.
XX
SQ Sequence 127 BP; 35 A; 30 C; 25 G; 36 T; 1 other;

Query Match 8.9%; Score 106; DB 19; Length 127;
Best Local Similarity 98.1%; Pred. No. 5.9e-17;
Matches 106; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy   1013 TGATGGTGATCTTGGCACTCTCCATGTTCTCTACAAGAAGCTGTGGTGATTGGCCCTGTG 1072
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    127 TGATGGTGATCTTGGCACTCTCCATGTTCTCTACAAGAAGCTGTGGTGATTGGCCCTGTG 68

Qy   1073 GTCTATCAGGCGAAAACCACAGATTCTCCTTCTAGTTAGTATAGCGCA 1120
          |||||:|||||||||||||||||||||||||||||||||||||| |
Db     67 GTCTAYCAGGCGAAAACCACAGATTCTCCTTCTAGTTAGTATAGCGGA 20
```